Nvidia stopped reporting Singapore sales figures as total revenues reached $104B, while the U.S. simultaneously tightened controls on remote access to AI technology. For healthcare AI deployments, this matters because access restrictions directly impact how organizations can leverage Nvidia's GPU infrastructure for clinical applications, particularly in distributed care settings or international partnerships. The opaque disclosure around specific regional sales reflects geopolitical pressures that will shape which healthcare systems can procure cutting-edge inference capabilities for real-time clinical decision support. Healthcare AI consultants should anticipate potential procurement delays and explore alternative GPU vendors or on-premise deployment models as export controls become a material risk factor in infrastructure planning.